vs
Cardlytics, Inc.（CDLX）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Cardlytics, Inc.的1.5倍（$75.5M vs $50.9M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -25.5%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $13.0M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -9.6%）
Cardlytics是一家领先的购买智能与广告技术企业，与多家大型银行合作分析匿名消费者交易数据，为消费品牌、零售商及服务商提供基于真实消费行为的精准效果广告投放服务，核心业务覆盖北美与英国地区。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CDLX vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.5倍
$50.9M
营收增速更快
PBYI
高出53.2%
-25.5%
自由现金流更多
PBYI
多$1.4M
$13.0M
两年增速更快
PBYI
近两年复合增速
-9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.9M | $75.5M |
| 净利润 | — | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | -12.0% | 22.7% |
| 净利率 | — | — |
| 营收同比 | -25.5% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.15 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDLXPBYI
| Q4 25 | $50.9M | $75.5M | ||
| Q3 25 | $47.0M | $54.5M | ||
| Q2 25 | $58.0M | $52.4M | ||
| Q1 25 | $56.4M | $46.0M | ||
| Q4 24 | $68.3M | $59.1M | ||
| Q3 24 | $61.1M | $80.5M | ||
| Q2 24 | $64.0M | $47.1M | ||
| Q1 24 | $62.2M | $43.8M |
净利润CDLXPBYI
| Q4 25 | — | — | ||
| Q3 25 | $-72.7M | $8.8M | ||
| Q2 25 | $-9.3M | $5.9M | ||
| Q1 25 | $-13.3M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-145.2M | $20.3M | ||
| Q2 24 | $-4.3M | $-4.5M | ||
| Q1 24 | $-24.3M | $-4.8M |
毛利率CDLXPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率CDLXPBYI
| Q4 25 | -12.0% | 22.7% | ||
| Q3 25 | -146.6% | 17.6% | ||
| Q2 25 | -22.0% | 12.7% | ||
| Q1 25 | -24.9% | 8.7% | ||
| Q4 24 | -12.2% | 22.6% | ||
| Q3 24 | -243.1% | 27.4% | ||
| Q2 24 | -24.7% | -4.6% | ||
| Q1 24 | -36.7% | -5.3% |
净利率CDLXPBYI
| Q4 25 | — | — | ||
| Q3 25 | -154.7% | 16.2% | ||
| Q2 25 | -16.0% | 11.2% | ||
| Q1 25 | -23.5% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -237.6% | 25.2% | ||
| Q2 24 | -6.7% | -9.6% | ||
| Q1 24 | -39.0% | -11.0% |
每股收益（稀释后）CDLXPBYI
| Q4 25 | $-0.15 | $0.26 | ||
| Q3 25 | $-1.36 | $0.17 | ||
| Q2 25 | $-0.18 | $0.12 | ||
| Q1 25 | $-0.26 | $0.06 | ||
| Q4 24 | $-0.36 | $0.40 | ||
| Q3 24 | $-2.90 | $0.41 | ||
| Q2 24 | $-0.09 | $-0.09 | ||
| Q1 24 | $-0.56 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $48.7M | $97.5M |
| 总债务越低越好 | $212.6M | $22.7M |
| 股东权益账面价值 | $-6.5M | $130.3M |
| 总资产 | $285.6M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CDLXPBYI
| Q4 25 | $48.7M | $97.5M | ||
| Q3 25 | $44.0M | $94.4M | ||
| Q2 25 | $46.7M | $96.0M | ||
| Q1 25 | $52.0M | $93.2M | ||
| Q4 24 | $65.6M | $101.0M | ||
| Q3 24 | $67.0M | $96.7M | ||
| Q2 24 | $71.2M | $96.8M | ||
| Q1 24 | $97.8M | $107.2M |
总债务CDLXPBYI
| Q4 25 | $212.6M | $22.7M | ||
| Q3 25 | $214.6M | $34.0M | ||
| Q2 25 | $214.3M | $45.3M | ||
| Q1 25 | $213.9M | $56.7M | ||
| Q4 24 | $213.6M | $68.0M | ||
| Q3 24 | $213.2M | $79.3M | ||
| Q2 24 | $212.9M | $90.7M | ||
| Q1 24 | $257.9M | $102.0M |
股东权益CDLXPBYI
| Q4 25 | $-6.5M | $130.3M | ||
| Q3 25 | $-4.7M | $115.3M | ||
| Q2 25 | $58.7M | $104.7M | ||
| Q1 25 | $64.1M | $97.1M | ||
| Q4 24 | $70.0M | $92.1M | ||
| Q3 24 | $69.7M | $71.1M | ||
| Q2 24 | $210.0M | $48.5M | ||
| Q1 24 | $199.1M | $51.0M |
总资产CDLXPBYI
| Q4 25 | $285.6M | $216.3M | ||
| Q3 25 | $292.8M | $202.9M | ||
| Q2 25 | $361.1M | $194.9M | ||
| Q1 25 | $369.1M | $196.2M | ||
| Q4 24 | $392.7M | $213.3M | ||
| Q3 24 | $399.4M | $220.7M | ||
| Q2 24 | $534.4M | $205.0M | ||
| Q1 24 | $569.0M | $214.1M |
负债/权益比CDLXPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | 3.65× | 0.43× | ||
| Q1 25 | 3.34× | 0.58× | ||
| Q4 24 | 3.05× | 0.74× | ||
| Q3 24 | 3.06× | 1.12× | ||
| Q2 24 | 1.01× | 1.87× | ||
| Q1 24 | 1.29× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.0M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $13.0M | $14.4M |
| 自由现金流率自由现金流/营收 | 25.5% | 19.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $8.8M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CDLXPBYI
| Q4 25 | $13.0M | $14.4M | ||
| Q3 25 | $1.8M | $9.7M | ||
| Q2 25 | $1.2M | $14.1M | ||
| Q1 25 | $-6.7M | $3.6M | ||
| Q4 24 | $3.0M | $15.6M | ||
| Q3 24 | $1.4M | $11.0M | ||
| Q2 24 | $4.4M | $1.0M | ||
| Q1 24 | $-17.6M | $11.2M |
自由现金流CDLXPBYI
| Q4 25 | $13.0M | $14.4M | ||
| Q3 25 | $1.7M | $9.7M | ||
| Q2 25 | $903.0K | $14.1M | ||
| Q1 25 | $-6.8M | $3.6M | ||
| Q4 24 | $2.9M | $15.6M | ||
| Q3 24 | $878.0K | $11.0M | ||
| Q2 24 | $4.1M | $1.0M | ||
| Q1 24 | $-18.3M | — |
自由现金流率CDLXPBYI
| Q4 25 | 25.5% | 19.1% | ||
| Q3 25 | 3.7% | 17.7% | ||
| Q2 25 | 1.6% | 26.8% | ||
| Q1 25 | -12.1% | 7.7% | ||
| Q4 24 | 4.2% | 26.4% | ||
| Q3 24 | 1.4% | 13.7% | ||
| Q2 24 | 6.5% | 2.1% | ||
| Q1 24 | -29.4% | — |
资本支出强度CDLXPBYI
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.8% | 0.0% | ||
| Q2 24 | 0.4% | 0.0% | ||
| Q1 24 | 1.0% | 0.0% |
现金转化率CDLXPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
